Abstract
Recombinant adeno-associated viral vectors (rAAV) have now been used in several clinical trials to treat a variety of diseases, and are currently the preferred choice of many investigators in the field, due to both their low pathogenicity and immunogenicity compared with other viral vectors, as well as localized long-term gene expression, despite their limitations of DNA size packaging and speed of expression. Recently, a number of advances have led to new generations of rAAV vectors, with improved features. This review addresses the various strategies employed to such effect, namely exploring distinct serotype tropisms, the production of mosaic and chimeric capsids, the selection of vectors through directed evolution, the development of self-complementary vectors, the use of pharmacological adjuvants and the induction of specific capsid mutations. Such approaches are expected to help the establishment of rAAV-based clinical gene therapy in the near future.
Keywords: Viral vectors, adeno-associated virus, directed evolution, selective mutagenesis, gene transfer, safety, efficacy.
Current Gene Therapy
Title:Advances in Recombinant Adeno-Associated Viral Vectors for Gene Delivery
Volume: 13 Issue: 5
Author(s): Hilda Petrs-Silva and Rafael Linden
Affiliation:
Keywords: Viral vectors, adeno-associated virus, directed evolution, selective mutagenesis, gene transfer, safety, efficacy.
Abstract: Recombinant adeno-associated viral vectors (rAAV) have now been used in several clinical trials to treat a variety of diseases, and are currently the preferred choice of many investigators in the field, due to both their low pathogenicity and immunogenicity compared with other viral vectors, as well as localized long-term gene expression, despite their limitations of DNA size packaging and speed of expression. Recently, a number of advances have led to new generations of rAAV vectors, with improved features. This review addresses the various strategies employed to such effect, namely exploring distinct serotype tropisms, the production of mosaic and chimeric capsids, the selection of vectors through directed evolution, the development of self-complementary vectors, the use of pharmacological adjuvants and the induction of specific capsid mutations. Such approaches are expected to help the establishment of rAAV-based clinical gene therapy in the near future.
Export Options
About this article
Cite this article as:
Petrs-Silva Hilda and Linden Rafael, Advances in Recombinant Adeno-Associated Viral Vectors for Gene Delivery, Current Gene Therapy 2013; 13 (5) . https://dx.doi.org/10.2174/15665232113136660028
DOI https://dx.doi.org/10.2174/15665232113136660028 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design AAV Hybrid Serotypes: Improved Vectors for Gene Delivery
Current Gene Therapy Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
Clinical Cancer Drugs Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Current Drug Targets Anticancer Properties of Asian Water Monitor Lizard (Varanus salvator), Python (Malayopython reticulatus) and Tortoise (Cuora kamaroma amboinensis)
Anti-Cancer Agents in Medicinal Chemistry To Be, or Not To Be: That is the Question-Lineage Commitment in Hematopoiesis
Current Immunology Reviews (Discontinued) Radioembolization of Hepatocellular Carcinoma
Current Drug Discovery Technologies Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)
Current Cancer Drug Targets Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews The Delivery of Biologically Active (Therapeutic) Peptides and Proteins into Cells
Current Medicinal Chemistry Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma
Current Cancer Drug Targets Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Optical Image-Guided Cancer Therapy
Current Pharmaceutical Biotechnology Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Developmental Immunotoxicity (DIT) in Drug Safety Testing: Matching DIT Testing to Adverse Outcomes and Childhood Disease Risk
Current Drug Safety Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism